MetaCap

Immunic (IMUX) vs MacroGenics (MGNX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MacroGenics (MGNX) has outperformed Immunic (IMUX) over the past year, gaining 40.0% versus a gain of 1.9%. Over five years, MGNX leads with a -89.6% price change compared with -91.9% for IMUX. MacroGenics is the larger company by market cap ($125.3 million vs $111.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMUX+1.90%MGNX+40.00%
+261%+111%-39%
Nov 21, 20251 yearNov 20, 2026
IMUX-92.54%MGNX-89.43%
+52%-25%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMUX versus MGNX key metrics
MetricIMUXMGNX
Share price$6.99$1.96
Market cap$111.01M$125.26M
1-day change-5.41%-1.01%
YTD return+30.90%+21.74%
1-year return+1.90%+40.00%
5-year return-91.88%-89.56%
EPS (TTM)$-3.53$-2.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$149.50M
Revenue growth (YoY)—-0.31%
Net income (latest FY)$-97.17M$-74.62M
Gross margin—100.00%
Operating margin—-48.72%
Net margin—-49.91%
52-week high$17.43$5.08
52-week low$5.06$1.32
Distance from 52-week high-59.90%-61.42%
Analyst consensusstrong_buybuy
Avg. price target upside+508.73%+308.16%
Average volume343.44K747.02K
Shares outstanding15.88M63.91M
Employees100293
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MGNX has outperformed IMUX by 38.1 percentage points over the past year.

About Immunic

IMUX stock →

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

About MacroGenics

MGNX stock →

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.

Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees

IMUX vs MGNX FAQ

Which is bigger, Immunic or MacroGenics?

MacroGenics (MGNX) is larger, with a market capitalization of $125.26M compared with $111.01M for Immunic (IMUX).

Which stock has performed better over the past year, IMUX or MGNX?

MGNX returned +40.00% over the past 12 months, compared with +1.90% for IMUX (price return, excluding dividends). Past performance does not predict future results.

Are Immunic and MacroGenics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons